【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology
Download our PDX Model poster presented at AACR 2025 1. Background of PDX-Derived Organoids 1.1 Historical evolution Patient-derived xenograft (PDX) models, pioneered in the 1960s by Rygaard and Poulsen, marked a significant advancement in oncology by preserving human tumor genetics in immunodeficient mice [1]. These models facilitated in vivo drug resistance studies but were hindered […]
China &US Dual Filing Secured! Medicilon Supports Sungening’s SG-1001 in Achieving FDA IND Clearance
June 27, 2025– SG-1001, an antifungal developed by Sungening, has received IND clearance from the U.S. FDA to initiate Phase I clinical trials. It follows its earlier clinical approval in China, making a significant milestone, dual IND clearances in both countries. This milestone not only marks a critical step in Sungening’s global strategy but also […]
Peptide Therapeutics: Preclinical Strategy
The CBA China Annual Conference 2025 successfully concluded in Suzhou on June 28, gathering over 30,000 professionals across 120+ forums to explore technological advancements and global collaboration. Dr. Hanjun Zou, TFM of Medicilon Chuansha, presented “Peptide Therapeutics: Preclinical Strategy,” detailing non-clinical research strategies for peptide drugs to accelerate their development and to improve treatment options. […]
【Blog】PDX-Derived Organoids: How This Mini-Tumor Transforming Cancer Research?
Imagine if we could grow tiny versions of a patient’s tumor in the lab, acting almost exactly like the real thing. PDXOs, the lab-growing 3D models, are not just cool science, they are changing how we discover and test disease treatment. Download our PDX Model poster presented at AACR 2025 So, what exactly are PDXOs? […]
Medicilon Highlights at the 2025 CBA-China Conference
June 28, 2025 –The Chinese Biopharmaceutical Association (CBA-China) Annual Conference concluded successfully in Suzhou, gathering over 1200 leaders from political, industrial, academic, and research sectors to explore technological advancements and global collaboration. Medicilon at CBA-China 2025: Showcasing Innovation & Global Leadership As a leading full-service preclinical R&D CRO, Medicilon actively participated in the CBA-China 2025 […]
Medicilon Supports BIOTIME in Securing Dual China-US Approvals for CDC7 Inhibitor BIOT-006
In April 2025, BIOTIME announced that its CDC7 inhibitor, BIOT-006, has received clinical trial approval from the U.S. FDA, following approval from China NMPA in March. No CDC7 inhibitor has yet been marketed globally to date. Medicilon, BIOTIME ‘s strategic partner, provided end-to-end preclinical R&D services for BIOT-006, from drug discovery to IND filing. This […]
BIK Therapeutics and Medicilon Sign Strategic Collaboration Agreement to Accelerate Oncology Drug Innovation.
May 13, 2025 –BIK Therapeutics, a South Korean biotech company pioneering next-generation oncology therapies, has entered a strategic collaboration with Medicilon to accelerate preclinical development of its lead candidates. Under the agreement, Medicilon will provide BIK Therapeutics with integrated preclinical research services, including pharmacokinetics, toxicology, and oncology pharmacology research. This includes key studies such as […]
Boston Innovation Meets ADME Precision
Smarter ADME Screening. Flexible Bundle. Greater Confidence. Flexible Screening Panels That Evolve With Your Pipeline. We get it – early discovery is fast-moving and complex. That’s why our bundled in vitro ADME panels are designed for your workflow, whether you choose one, two, or a full suite. Speed, Clarity, and Tailored Flexibility. and we are […]
Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence
Shanghai, May 20, 2025 – Medicilon Preclinical Research (Shanghai) LLC (“Medicilon”) announces that it has successfully passed an on-site inspection by the FDA. The company receives an official Establishment Inspection Report (EIR) reaffirming its position as a trusted leader in preclinical R&D services. A Milestone of Compliance and Capability The FDA inspection, conducted with meticulous […]
Empowering Innovation in Regenerative Medicine: Medicilon’s ELU42 IND Team Wins Eluciderm’s “Excellent Service Award”
Medicilon has been honored with the “Excellent Service Award” by its client, Eluciderm Inc., in recognition of their exceptional capabilities of Medicilon’s Elu42 IND team and their high-quality contributions to the development of the innovative therapy, Elu42. Testimony from Eluciderm CEO, Dr. Dan Holsworth: Dear Medicilon Elu42 IND team, I wanted to let you know […]
